Gliadel for brain metastasis

Surgical Neurology International

Volumn 4, Issue SUPPL4, 2013, Pages

  Abel, Taylor ^a   Ryken, Timothy ^b   Lesniak, Maciej ^c   Gabikian, Patrik ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b Iowa Spine and Brain Institute   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

BCNU polymer wafer; brain metastasis; Brain tumor; gliadel chemotherapy; local delivery

Indexed keywords

CARMUSTINE; POLYMER;

ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED DRUG RELEASE; HUMAN; LIFE EXPECTANCY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS;

EID: 84877935530     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.111305     Document Type: Article

References (59)

1. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006;7:41-53
2. Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience. Ann Surg Oncol 2008;15:2887-93
3. Barker FG, 2 nd. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: Decreasing mortality and the effect of provider caseload. Cancer 2004;100:999-1007
4. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. The blood-brain barrier and oncology: New insights into function and modulation. Cancer Treat Rev 2000;26:449-62
5. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol 1995;26:111-23
6. Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 2001;74:63-7
7. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995;345:1008-12
8. Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, et al. Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 1994;80:283-90
9. Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood-brain barrier in anaesthetized rats: A developmental study. J Physiol 1990;429:47-62
10. Carey LA, Ewend MG, Metzger R, Sawyer L, Dees EC, Sartor CI, et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 2004;88:273-80
11. Chamberlain MC. Anticancer therapies and CNS relapse: Overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability. Expert Rev Neurotherap 2010;10:547-61
12. Counsell CE, Collie DA, Grant R. Incidence of intracranial tumours in the Lothian region of Scotland, 1989-90. J Neurol Neurosurg Psychiatry 1996;61:143-50
13. Deeken JF, Loscher W. The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin Cancer Res 2007;13:1663-74
14. Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 2005;31:312-8
15. Ewend MG, Brem S, Gilbert M, Goodkin R, Penar PL, Varia M, et al. Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007;13:3637-41
16. Ewend MG, Sampath P, Williams JA, Tyler BM, Brem H. Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 1998;43:1185-93
17. Ewend MG, Williams JA, Tabassi K, Tyler BM, Babel KM, Anderson RC, et al. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 1996;56:5217-23
18. Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain metastases from solid tumors: Disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res 2011;30:10
19. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: Establishing a treatment paradigm. J Clin Oncol 2007;25:2306-12
20. Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: A clinico-pathologic study. J Neurooncol 2000;50:265-73
21. Golden GA, Meldorf M, Group. at PS. Patients with metastatic brain cancer undergoing resection and GLIADEL implantation experienced low local recurrence rates in the PROLONG registry. Neurooncology 2004;6:307-400
22. Graf AH, Buchberger W, Langmayr H, Schmid KW. Site preference of metastatic tumours of the brain. Virchows Arch A Pathol Anat Histopathol 1988;412:493-8
23. Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992;76:640-7
24. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
25. Lampson LA. Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier. MAbs 2011;3:153-60
26. Langer R, Brem H, Tapper D. Biocompatibility of polymeric delivery systems for macromolecules. J Biomed Mater Res 1981;15:267-77
27. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature 1976;263:797-800
28. Lassman AB, DeAngelis LM. Brain metastases. Neurol Clin 2003;21:1-23
29. Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res 1985;19:941-55
30. Li KW, Dang W, Tyler BM, Troiano G, Tihan T, Brem H, et al. Polilactofate microspheres for Paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 2003;9:3441-7
31. Long DM. Capillary ultrastructure in human metastatic brain tumors. J Neurosurg 1979;51:53-8
32. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009;110:583-8
33. Moscetti L, Nelli F, Felici A, Rinaldi M, De Santis S, D′Auria G, et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: Survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer 2007;109:274-81
34. Nagpal S. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. Neurosurg Clin North Am 2012;23:289-95
35. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012;14:48-54
36. Newton HB, Volpi C, Burkart J, Miner ME, Gahbauer R, Pearl DK, et al. Phase III randomized multicenter trial of surgical resection, BCNU-impregnated wafers, and irradiation versus surgical resection and irradiation alone for treatment of operable, solitary brain metastasis from systemic cancer. J Clin Oncol 2006;24:11513
37. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996;78:1781-8
38. O′Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, et al. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17:2752-61
39. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998;280:1485-9
40. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500
41. Patel AJ, Suki D, Hatiboglu MA, Abouassi H, Shi W, Wildrick DM, et al. Factors influencing the risk of local recurrence after resection of a single brain metastasis. J Neurosurg 2010;113:181-9
42. Petropoulos S, Gibb W, Matthews SG. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation. Brain Res 2010;1357:9-18
43. Pradilla G, Wang PP, Gabikian P, Li K, Magee CA, Walter KA, et al. Local intracerebral administration of Paclitaxel with the paclimer delivery system: Toxicity study in a canine model. J Neurooncol 2006;76:131-8
44. Ryken T. Implantable polymeric BCNU as an adjunt to surgery for metastatic intracranial disease. European Congress of Neurosurgery (EANS); September 2-7; Glasgow, UK2007
45. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002;94:2698-705
46. Scott AW, Tyler BM, Masi BC, Upadhyay UM, Patta YR, Grossman R, et al. Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials 2011;32:2532-9
47. Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H. Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 1993;53:329-33
48. Tamargo RJ, Sills AK, Jr., Reinhard CS, Pinn ML, Long DM, Brem H. Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. J Neurosurg 1991;74:956-61
49. Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: A comprehensive review. Crit Rev Oncol Hematol 2004;52:199-215
50. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 1997;41:44-9
51. Vecht CJ. Clinical management of brain metastasis. J Neurol 1998;245:127-31
52. Wang W, Dentler WL, Borchardt RT. VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 2001;280:H434-40
53. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-20
54. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: New approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2007;25:399-404
55. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 2003;5:79-88
56. Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir 2006;148:269-5
57. Yang M, Baranov E, Jiang P, Sun FX, Li XM, Li L, et al. Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc Natl Acad Sci U S A 2000;97:1206-11
58. Yang MB, Tamargo RJ, Brem H. Controlled delivery of 1,3-bis (2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. Cancer Res 1989;49:5103-7
59. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 1992;141:1115-24